← All indications
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
Subtype terms (5)
More specific conditions that are subtypes of Heart Failure in the MeSH hierarchy.
- Cardio-Renal Syndrome
22 drugs (19 approved, 3 experimental)
- Dyspnea, Paroxysmal
2 drugs approved
- Edema, Cardiac
2 drugs (1 approved, 1 experimental)
- Heart Failure, Diastolic
139 drugs (75 approved, 64 experimental)
- Heart Failure, Systolic
91 drugs (57 approved, 34 experimental)
Drugs by status
Approved for this indication (71)
- reteplase
- levosimendan
- olmesartan
- sacubitril
- eplerenone
- brain natriuretic peptide
- foxglove
- valsartan
- nitroglycerin
- chlorthalidone
- chixiangshen tongxin
- spironolactone
- dapagliflozin
- fosinopril
- nitroprusside
- enalapril
- digoxin
- metoprolol
- metolazone
- dopexamine
- sodium chloride
- perindopril
- chlorothiazide
- acetyldigitoxin
- captopril
- ivabradine
- flosequinan
- etacrynic acid
- conivaptan
- dobutamine
- +41 more
Phase 4 trials (98)
- prednisone
- levothyroxine
- incretin
- heparin
- irbesartan
- inactivated influenza vaccine
- aprepitant
- indacaterol
- Ocedurenone
- benzbromarone
- bisoprolol
- canrenone
- shensong yangxin
- sofosbuvir
- insulin glargine
- p-aminohippuric acid
- potassium
- pitavastatin
- zolpidem
- landiolol
- pegvisomant
- sildenafil
- rosuvastatin
- saxagliptin
- telmisartan
- exenatide
- iohexol
- regadenoson
- vilanterol
- enavogliflozin
- +68 more
Phase 3 trials (88)
- relaxin
- zirconium silicate
- urodilatin ularitide
- human placental derived stem cells
- acetylcysteine
- autologous skeletal myoblast
- potassium perchlorate
- anakinra
- adenovirus-5 encoding human adenylyl cyclase type 6
- ips differentiated cardiomyocytes
- neuregulin
- albumin (Human)
- crataegus
- arginine
- valganciclovir
- cardiamp
- finerenone
- tonapofylline
- mirabegron
- von Willebrand factor
- potassium iodide
- omecamtiv mecarbil
- ranolazine
- levofloxacin
- human factor ix complex (prothrombin complex concentrate)
- vitamin c
- TRC 4186
- ziltivekimab
- buspirone
- growth hormone
- +58 more
Phase 2 trials (154)
- olbetam
- melatonin
- bifidobacterium animalis
- yiqi
- bc 007
- liothyronine
- ghrelin
- pb1046
- bay1067197
- macitentan
- bupivacaine
- elamipretide
- ubiquinol
- beetroot juice
- bone marrow derived mononuclear cells
- pyridostigmine bromide
- betatropin
- xenon-129
- hs-001 cs
- azd5462
- autologous serum
- glucose monohydrate
- imb-1018972
- cdr132l
- autologous cd133+ stem cells
- jtt-861
- jnj-39588146
- azd4831
- hicm-188
- ly3540378
- +124 more
Phase 1 trials (70)
- yanxinshi
- itraconazole
- tetrahydrobiopterin
- allorx stem cells®
- glucagon-like peptide-1
- human (allogeneic) ips-cell-derived cardiomyocyte
- hrs-9057
- prazosin
- angiogenic cell precursors
- autologous cd34+ cells
- phentolamine mesylate
- anginera
- fenoterol
- cor-1
- glial growth factor 2
- nitric acid
- beta-hydroxybutyrate
- ozanimod
- leo 152020
- ckd-349
- astragalus membranaceus
- daratumumab
- autologous adipose-derived mesenchymal stem cells
- inxn-4001
- anx-042
- maltodextrin
- lysine
- trimetazidine
- midazolam
- hm2002
- +40 more
Other trials (54)
- loperamide
- edoxaban
- zhenyuan
- sapropterin
- palmitic acid
- acetic acid
- oseltamivir
- water
- atenolol
- whey protein
- apelin
- 15o water
- glycopyrronium
- isoprenaline
- urocortin
- nicorandil
- sorbitol
- creatine
- ringer's lactate
- propafenone
- amyl nitrite
- l-epigallocatechin
- gelofusin
- substance p
- diltiazem
- amisometradine
- epicatechin
- codeine
- sotalol
- acacia
- +24 more
Organizations
Organization Involved with Phase 4 Indications (263)
- Cancer Research Network
- Mayo Clinic
- British Heart Foundation
- University of Florida
- Yeshiva University
- Cocco, Giuseppe, M.D.
- National Taiwan University
- Queen's University, Belfast
- Hebei University
- Cytel Inc.
- Government of Taiwan
- Catholic University of Korea
- Peking University
- University of North Carolina at Chapel Hill
- University of Montreal
- The Christ Hospital
- Aarhus University
- University of Texas, Galveston
- Tottori University
- University of Toronto
- Danderyds Hospital
- University of Zagreb
- Heart and Stroke Foundation of Canada
- Tianjin Medical University
- University of Foggia
- I-Shou University
- Scripps
- Vestfold Hospital
- National Cheng Kung University
- Cornell University
- +233 more
Organization Involved with Phase 3 Indications (161)
- Hospital Regional Universitario Carlos Haya
- OLV Hospital, Aalst, Belgium
- Bayer
- Cardiorentis
- IQVIA
- Mesoblast, Inc.
- CTI Clinical Trial and Consulting Services
- Semmelweis University
- Maisel, Alan, M.D.
- Paracelsus Medical University
- Department of Health and Human Services
- INC Research
- Shandong Province Qianfoshan Hospital
- Yooyoung Pharmaceutical Co.,Ltd.
- Servier
- RWTH Aachen University
- Spanish Society of Cardiology
- Hospital dos Servidores do Estado - Rio de Janeiro
- Corthera
- National Heart Foundation, Australia
- Ethicare GmbH
- Gruppo di Ricerca GISSI
- Caritas Teaching Hospital, Bucharest
- University of Naples Frederico II
- Momentum Research, Inc.
- Shanghai Putuo District Central Hospital
- University of Pittsburgh
- TFS Trial Form Support
- University of Burgundy
- Cardiome Pharma
- +131 more
Organization Involved with Phase 2 Indications (163)
- CoreQuest, Switzerland
- Government of Italy
- Medical Centre Dinasty
- Iv Military Hospital, Wroclaw
- Medical City Children's Hospital, Dallas
- RiboCor, Inc.
- Texas Heart Institute
- Government of Iran
- European Union
- Sclnow Biotechnology Co., Ltd.
- IUPUI
- CardioCell LLC
- Innolife Co., Ltd.
- Policlinico Milano
- Forest Laboratories
- Cedars-Sinai Medical Center
- Tennessee Center for Clinical Trials
- Fluminense Federal University
- Innogene Kalbiotech Pte. Ltd
- GREAT Network Italy
- San Diego Cardiac Center
- American Academy of Sleep Medicine
- Washington University in St. Louis
- University of Turku
- Wexham Park Hospital
- Bambino Gesù Hospital and Research Institute
- Tenax Therapeutics, Inc.
- Insitutul de Boli Cardiovasculare C.C. Iliescu Bucuresti, Bucharest - ROMANIA
- Solvay
- University of Jena
- +133 more
Organization Involved with Phase 1 Indications (40)
- Bial
- The Atlanta Cardiology Group, PC
- Cardiovascular Specialists PC dba New York Heart Ctr
- Richmond Pharmacology
- McGill University
- University of Ankara
- Intrexon
- Henry Ford Health System
- MyoKardia, Inc.
- Glendale Adventist Medical Center
- Facet Biotech
- Hennepin Healthcare
- Salubris Biotherapeutics Inc
- Acusphere
- Olatec Industries LLC
- Sarfez Pharmaceuticals, Inc.
- Theregen, Inc.
- Harbin Medical University
- Maastricht University
- University of Louisville
- Bangkok Heart Hospital
- TransThera Biosciences Co., Ltd
- Arbor Pharmaceuticals
- Integrium
- Texas Health Resources
- Kore Cardiovascular Research Institute
- Cardior Pharmaceuticals GmbH
- Papworth Hospital NHS Foundation Trust
- ABX-CRO
- Parexel
- +10 more
Organization Involved with Other Experimental Indications (60)
- Tianjin University of Traditional Chinese Medicine
- Brown University
- St. Antonius Hospital, Nieuwegein
- University of Leicester
- National Institute of Cardiology, Laranjeiras, Brazil
- Sint Antonius Hospital, Nieuwegein
- National Institute of Nursing Research (NINR)
- Sadat City University
- Arizona State University
- Alere Wellbeing
- Valen Labs
- Shantou University
- Biomarin
- Nanjing University
- Texas Tech University
- Gambro
- ResMed
- Luzerner Kantonsspital
- Instituto Nacional de Enfermedades Respiratorias
- Loughborough University
- University of Caen-Normandie
- Fraser Health
- The Hershey Company
- Herlev Hospital
- Gia Dinh People Hospital
- Scottsdale Cardiovascular Research Institute
- Hokkaido University
- Xinxiang Medical University
- Chinese University of Hong Kong
- Instituto Nacional De Enfermedades Respiratorias Ismael Cosio Villegas
- +30 more